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Abstract
PPARs are nuclear receptors activated by ligands. Activation of PPARc leads to a reduction of adhesion and motility in some
cancer models. PPARc transcriptional activity can be negatively regulated by JNK-mediated phosphorylation. We postulated
that the use of agents able to inhibit JNK activity could increase the effectiveness of PPARc ligands. We analysed the effects
of rosiglitazone (PPARc ligand) and AS601245 (a selective JNK inhibitor) alone or in association on adhesion and migration
of CaCo-2, HT29, and SW480 human colon cancer cells and investigated, through microarray analysis, the genes involved in
these processes. Cell adhesion and migration was strongly inhibited by rosiglitazone and AS601245. Combined treatment
with the two compounds resulted in a greater reduction of the adhesion and migration capacity. Affymetrix analysis in
CaCo-2 cells revealed that some genes which were highly modulated by the combined treatment could be involved in these
biological responses. Rosiglitazone, AS601245 and combined treatment down-regulated the expression of fibrinogen chains
in all three cell lines. Moreover, rosiglitazone, alone or in association with AS601245, caused a decrease in the fibrinogen
release. ARHGEF7/b-PIX gene was highly down-regulated by combined treatment, and western blot analysis revealed that
b-PIX protein is down-modulated in CaCo-2, HT29 and SW480 cells, also. Transfection of cells with b-PIX gene completely
abrogated the inhibitory effect on cell migration, determined by rosiglitazone, AS601245 and combined treatment. Results
demonstrated that b-PIX protein is involved in the inhibition of cell migration and sustaining the positive interaction
between PPARc ligands and anti-inflammatory agents in humans.
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Introduction
PPARc belongs to the nuclear receptor superfamily consisting of
a group of approximately 50 transcription factors involved in
many different biological processes and considered as important
targets in the development of new drugs [1]. The PPARc
activation by agonists regulates lipid storage in adypocytes [2],
inhibits proliferation and induces differentiation and apoptosis in a
number of cancer cells [3]. Thus, the PPARc ligands have been
considered as potential drugs for different types of cancer.
Endogenous PPARc ligands include unsaturated fatty acids and
several prostanoids such as 15-deoxy-prostaglandin J2 (15d-PGJ2)
and 15-hydroxy-eicosatetranoic acid (HETE), which are metab-
olites of arachidonic acid [4]. Synthetic ligands comprise the
insulin-sensitizing thiazolindinedione (TZD) class (troglitazone,
pioglitazone and rosiglitazone) that are used to treat diabetes
mellitus [5–6] and several non-steroidal anti-inflammatory drugs
(NSAIDs), in particular indomethacin and ibuprofen, that are
weak PPARc agonists at high micromolar concentrations [7].
The sensitivity of the different cell types to PPARc ligands
mostly depends on the PPARc expression and activity. High levels
of PPARc expression have been reported in adipose and colon
tissues. The latter is the major tissue expressing PPARc in
epithelial tissues [1]. Despite this observation, the number of
studies investigating PPARc in human subjects with colon cancer
is limited. In specimens from colon cancer patients, immunohis-
tochemical analysis demonstrated a correlation between PPARc
and cell cycle-related molecules but no association was detected
between PPARc and patient survival [8]. More recently, Ogino
and collaborators demonstrated, in colorectal cancer patients, that
the expression of PPARc is associated with a good prognosis [9], in
accordance with the previous data reported by Jackson and
collaborators [10], which demonstrated that PPARc (mRNA and
protein) expression levels were significantly depressed in colorectal
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cancer cells compared with matched non-malignant tissue. In
animal studies, a deficiency in intestinal PPARc was associated
with enhanced tumorigenicity in small intestine and colon of
ApcMin/+ mice [11]. Similarly, in mouse models of colon cancer,
PPARc agonists inhibited tumor growth or colon carcinogenesis
[12–14]. These data support the hypothesis that PPARc ligands
may inhibit colorectal tumour progression and may be an
important therapeutic target.
One of the most important aspects in cancer progression, is the
acquisition of invasive behaviour, a multi-stage process which
involves cancer cells adhesion to the vassel endothelium and the
motility through the extracellular matrix. It has been demonstrat-
ed that PPARc agonists affect these parameters not only in the
control of cell inflammation [15] but also in several types of cancer
cells [16,17].
Besides ligand binding, PPARc genomic activity can be
modulated by various cellular processes.
Indeed, mitogenic hormones, growth factors and pro-inflam-
matory signals are all known to reduce the ability of PPARc to
respond to ligand stimulation. The mechanisms that control this
down regulation are complex and comprise phosphorylation [18],
ubiquitination [19], sumoylation [20] and cytoplasmic shuttling
[21]. A key down-regulating mechanism involves phosphorylation
by various mitogen activated kinases (MAPKs), which are central
signalling components in the regulation of cell proliferation,
differentiation survival, stress response and apoptosis [22]. In
particular, it has been reported that c-Jun-terminal kinase (JNK)
phosphorylates PPARc and negatively regulates its transcriptional
activity [23]. On the basis of these observations we postulated that
the use of agents able to inhibit JNK activity could increase the
effectiveness of PPARc ligands. AS601245 [1,3-Benzothiazol-2-yl-
(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetonitrile; JNK
inhibitor V] has been selected as a potent and selective JNK
inhibitor with anti-inflammatory properties [24], and has been
used in the present work to assess its involvement with anti-
carcinogenic effects displayed by rosiglitazone in colon cancer
cells. In particular, we examined the effects of rosiglitazone and
AS601245, alone or in association, on adhesion and migration of
human colon cancer cells, and investigated the genes involved in
the these processes, through microarray analysis (Affimetryx
GeneChip).
Materials and Methods
Ethics Statement
The use of HUVEC was approved by the Ethics Committee of
the ‘‘Presidio Ospedaliero Martini’’ of Turin and conducted in
accordance with the Declaration of Helsinki. Written informed
consent was obtained from all patients.
Cell Culture and Treatments
CaCo-2, SW480 and HT29 colon cancer cells were obtained
from European Collection of Cell Cultures (ECACC) and cultured
at 37uC in a humidified atmosphere of 5% CO2-air. ECACC
provides full quality control and authentication procedures for the
cell lines. These cell lines have been selected because they
represent three cell models with different potentials of invasiveness:
higher in HT29 cells, middle in Caco-2 cells and lower in SW480
cells. Cells were grown in D-MEM medium (CaCo-2 and SW480
cells) or McCoy’s medium (HT29 cells) supplemented with 10%
fetal calf serum (FCS, HyClone, Italy), 2 mM glutamine, 1% non
essential amino acids solution and 1% antibiotic mixture
(penicillin-streptomycin) (Sigma, Milano, Italy).
Figure 1. Cell proliferation. A. Effect of different doses of rosiglitazone (10, 50, 100, 200, 250 mM) on CaCo-2, HT29 and SW480 cell proliferation; B.
effect of different doses of AS601245 (0.1, 1, 2.5, 5, 10 mM) on CaCo-2, HT29 and SW480 cell proliferation. Values are detected by measuring the
luminescence released by the metabolically active cells. The values, expressed in RLUs are the means S.D. of three separate experiments.
doi:10.1371/journal.pone.0040149.g001
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Treatments with rosiglitazone and AS601245 [1,3-Benzothia-
zol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetoni-
trile; JNK inhibitor V] (SPRI, Geneva, Switzerland) were
performed by resuspending the drugs in DMSO. The concentra-
tion of vehicle in culture did not exceed 1%. Moreover, cultures,
treated with 1% DMSO alone, were performed to exclude the
vehicle’s effects.
HUVEC were isolated as described elsewhere [25] and cultured
on gelatin-coated culture dishes in M199 medium supplemented
with 20% heat-inactivated FCS, 100 U/ml penicillin, 100 mg/ml
Figure 2. Cell adhesion. Effect of different doses of rosiglitazone (0.01, 0.1, 1, 10, 50 mM), AS601245 (0.01, 0.1, 1, 10, 50 mM) and combined
treatment on CaCo-2, HT-28 and SW480 on cell adhesion to HUVECs. Cells were treated or not with the drugs for 24 hours, harvested and incubated
for 1 hour on HUVEC monolayers. Data are expressed as percentage of adhesion inhibition versus untreated control cells. The control value of
adhesion was about 5566 cells per microscope field (n = 6) for all cell lines. The values is the mean 6 SD, of 3 separated experiments. Variance
analysis: *p,0.05, **p,0.01 vs control; # p,0.05 vs rosiglitazone; ## p,0.01 vs rosiglitazone; 1 ,0.01 vs both compounds.
doi:10.1371/journal.pone.0040149.g002
Figure 3. Cell migration. Inhibition of tumour migration by a Boyden chamber assay. CaCo-2, HT29 and SW480 cells were plated onto the apical
side of Matrigel-coated filters in serum-free medium supplemented with drugs at different concentrations (0.1, 1, 10, 50 mM rosiglitazone; 0.1, 1, 10,
50 mM AS601245) and with the association of the drugs at different concentrations for 24 hours. Chemoattractant utilized was 20% FCS
supplemented medium, placed in the basolateral chamber. The cells migrated to the bottom of the filters were stained using crystalviolet and
counted (5 fields of each triplicate filters) using an inverted microscope. Control migration was 4568 cells/microscope fields for CaCo-2 cells, 5065
cells/microscope fields for HT29 and 4063 cells/microscope fields for SW480. Data are expressed as mean6SEM (n= 5) of the percentage of inhibition
versus the migration of cells exposed to vehicle (1% DMSO). Variance analysis *p,0.05, **p,0.01 vs control; a p,0.05, aa p,0.01 vs rosiglitazone; b
p,0.05, bb p,0.01 vs AS601245.
doi:10.1371/journal.pone.0040149.g003
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streptomycin, 5 U.I./ml heparin, 12 mg/ml bovine brain extract
and 200 mM glutamine. HUVEC were utilized at II-V passages.
Cell Proliferation and Viability
Cell proliferation was evaluated by the kit ‘‘CellTiter-Glo
Luminescent Cell Viability Assay’’ (Promega, Milano, Italy). This
assay detects the luminescence released by the metabolically active
cells. Quantification of luminescence was expressed as RLU
(Relative Light Unit). For the proliferation experiments, treat-
ments were performed by adding the drugs (at different
concentrations) to the cells seeded at about 4,000 cells/well in a
96-well plate.
Adhesion Assay
HUVEC were grown to confluence in 24-well plates, washed,
and left in place for one day in M199 medium plus 10% FCS.
Commercial fluorescent cell linker mini kit PKH67 (Sigma) was
used for membrane labeling of colon cancer cells. The staining
efficiency was monitored by fluorescent microscopy. Colon cancer
cells (CaCo-2, SW480 and HT29 cells) treated or untreated (24
hours) with rosiglitazone or AS601245 (50-0.01 mM) or both
substances, were harvested and labeled as described above, and
plated (1236105 cells/wells) in a final volume of 0.25 ml M199
medium on untreated HUVEC and left in place for 1 h at 37uC in
5% CO2. After incubation, non-adherent cells were removed by
washing 3 times with 1 ml M199 medium. The center of each well
was analyzed by fluorescence image analysis [26]. Adherent cells
were counted using Image Pro Plus Software for micro-imaging
(Media Cybernetics, version 5.0). Single experimental points were
assayed in quadruplicate, and the standard error of the four
replicates was below 10% in all cases.
Matrigel Migration Assay
Chemotaxis assay of cancer cells was performed by the Boyden
chamber method using a filter of 8.2 mm diameter and 5.0 mm
pore size (Neuro Probe, Inc.; BIOMAP snc, Milan Italy) coated
with 0.1 ml/ml Matrigel (BD MatrigelTM Matrix; BD Biosciences,
Oxford, UK). Briefly, medium containing 20% FCS as a
chemoattractant was placed in the lower wells. Initially, CaCo-2,
HT29 and SW480 cells (at final concentration of 5 x 104 cells/ml)
were suspended in the upper wells (about 4000 cells/well for
HT29 and 8000 cell/well for SW480 and CaCo-2) in serum-free
medium supplemented with drugs at different concentrations
(from 0.1 mM to 50 mM for both substances) and with the
association of the drugs at different concentrations. The migration
Figure 4. Venn Diagram. Gene expression in CaCo-2 cells treated
with 50 mM rosiglitazone, 0.1 mM AS601245 and the association of these
two compounds (Rosiglitazone + AS601245) was detected by micro-
array analysis 24 hours after the treatment. Venn diagram shows the
number of genes modulated by the treatments.
doi:10.1371/journal.pone.0040149.g004
Table 1. Biological functions.
ROSIGLITAZONE
Biofunction Genes p-value range #Genes
Cancer 1.20E212-1.84E202 304
Genetic Disorder 2.71E210-1.84E202 328
Gastrointestinal Disease 3.98E210-1.84E202 114
Cell Death 1.26E208-1.84E202 213
Cell Cycle 5.04E208-1.84E202 135
Cellular Assembly and Organization 1.30E205-1.84E202 103
Cellular Growth and Proliferation 1.38E205-1.84E202 233
Reproductive System Disease 1.69E205-1.84E202 150
Neurological Disease 1.98E205-1.69E202 175
Protein Trafficking 2.05E205-8.60E203 33
AS601245
Biofunction Genes p-value range #Genes
Cell Cycle 7.75E215-1.24E202 301
RNA Post-Transcriptional Modification 1.02E214-7.64E203 98
Cancer 3.54E214-1.24E202 658
Cell Death 1.46E213-1.07E202 511
Gastrointestinal Disease 4.37E211-1.13E202 214
Genetic Disorder 1.22E202-4.33E210 718
Cellular Growth and Proliferation 1.23E209-1.21E202 539
Molecular Transport 9.69E209-1.01E202 124
Respiratory Disease 1.09E208-7.87E–03 128
Neurological Disease 4.32E208-1.13E202 410
ROSIGLITAZONE +AS601245
Biofunction Genes p-value range #Genes
Cancer 8.05E213-1.60E202 314
Cell Death 9.65E213-1.60E202 229
Genetic Disorder 9.47E210-1.53E202 305
Gastrointestinal Disease 2.10E208-1.38E202 114
Cell Cycle 1.74E207-1.60E202 119
Cellular Growth and Proliferation 2.51E207-1.60E202 228
Amino Acid Metabolism 1.18E205-9.89E203 18
Small Molecule Biochemistry 1.18E205-1.53E202 85
Neurological Disease 1.81E205-1.55E202 179
Connective Tissue Disorders 2.78E205-1.60E202 51
Genes affected by 50 mM rosiglitazone, by 0.1 mM AS601245, and by the
combined treatment with rosiglitazone and AS601245, with respect to DMSO
treated CaCo-2 cells, arranged according to the relative biological functions.
doi:10.1371/journal.pone.0040149.t001
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of control untreated cells, cell exposed to the vehicle (1% DMSO)
and of control and treated cells exposed to mitomycin C (50 mg/
ml) (Sigma) was also analyzed. The chamber was incubated at
37uC under 5% CO2 for 24 hours. Chemotaxis was quantified by
counting the stained cells that migrated to the lower side of the
filter by using an optical microscope (magnification x 100). The
stained cells were counted as the mean number of cells per 5
random fields for each assay. Results are expressed as percentage
of the inhibition of treated cells versus the migration measured in
cell exposed to 1% DMSO. These conditions were maintained for
transfected cells, also.
Fibrinogen Release Determination
Fibrinogen (FBG) release in culture media was analysed by
using the AssayMax Human Fibrinogen (FBG) ELISE Kit from
Assaypro (St. Charles, MO, USA) according to the manufacturer’s
protocol.
CaCo-2 cells were grown in flasks and seeded at the
concentration of 4 x 106/flask. Cells, exposed to rosiglitazone
(50, 10 and 1 mM), AS601245 (0.1 mM) or both substances (50 mM
rosiglitazone and 0.1 mM AS601245), were harvested after 24
hours from the beginning of experiment and centrifuged. The
collected supernatants were incubated in a 96-well plate coated
with a polyclonal antibody specific for human FBG. FBG in
samples was sandwiched by the immobilized polyclonal antibody
and biotinylated polyclonal antibody specific for human FBG,
which was recognized by a streptavidin-peroxidase conjugate. All
unbound material was washed away and a peroxidase enzyme
substrate was added. The colour development was stopped and the
intensity of the colour was measured in a microplate reader at a
wavelength of 450 nm.
RNA Extraction and Array Hybridization
CaCo-2 cells were treated with vehicle (1% DMSO) or 50 mM
rosiglitazone or 0.1 mM AS601245 or rosiglitazone plus
AS601245 for 24 hours, and total RNA from 3 biological
replicates of each treatment was isolated using TRIzol reagent
(Invitrogen, Milano, Italy). Samples were treated with DNase in
order to avoid any genomic contamination. The quality of the
resulting RNA was determined by using the Agilent 2100
Bioanalyzer (Agilent Technologies). The RNA content was
normalized by using the Thermo Scientific NanoDropTM ND-
1000 spectrophotometer. RNA samples of each replicate were
analyzed by using Affymetrix GeneChip Human Genome
U133A plus 2.0 chips (Affymetrix). RNA amplification, double-
stranded cDNA synthesis and generation of biotin-labeled cRNA
by in vitro transcription (IVT) were performed according to the
manufacturer’s protocol using Affymetrix kits. The final cDNA
was checked for quality and quantity before fragmentation and
chip hybridization. Each chip was then washed and stained using
a Fluidics station 450 (Affymetrix). Fluorescence intensity for
each chip was captured with an Affymetrix GeneChip Scanner
3000 (Affymetrix). GCOS software version 1.2 (Affymetrix) was
used to define the probe cell and calculates the intensity for each
cell. CEL files generated, containing the summary intensities for
each probe, were analyzed through the following bioinformatics
approaches. We firstly assessed the overall data quality using R/
Bioconductor. Then, we loaded the dataset into the Rosetta
Resolver for data normalization, generation of expression values,
and statistical analysis. Expression values of all treatment groups
were obtained as ratio versus the negative control (1% DMSO).
Differential analyses between pairs of groups were performed
with 1-way ANOVA followed by the Benjamini-Hochberg
multiple testing correction (False Discovery Rate-FDR cut-off
of 1%) and a Student-Newman-Keuls post hoc analysis. Finally,
differentially expressed genes were analysed in Ingenuity Pathway
Analysis software version 7.5 (IngenuityH Systems, www.
ingenuity.com).
Figure 5. Fibrinogen release. Fibrinogen release in CaCo-2 cells
exposed to different concentration (1-10-50 mM) of rosiglitazone,
0.1 mM AS601245 or both substances (50 mM rosiglitazone and 0.1mM
AS601245). Data are expressed as percentage of fibrinogen release with
respect to the control value and is the mean 6 SD of 3 separate
experiments. Variance analysis: **p,0.01 vs control, # p,0.05 vs
rosiglitazone.
doi:10.1371/journal.pone.0040149.g005
Table 2. The top ten genes modulated by rosiglitazone.
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A,
polypeptide 1
+9.691
MT1X metallothionein 1X +6.064
MT1E metallothionein 1E +6.004
MT1G metallothionein 1G +5.627
MT1H metallothionein 1H +4.919
MT2A metallothionein 2A +4.446
CPT1A carnitine palmitoyltransferase 1A +4.247
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 2
+3.707
GANAB glucosidase, alpha; neutral AB +3.196
MT1M metallothionein 1M +2.799
FGA fibrinogen alpha chain 23.426
GAS2 growth arrest-specific 2 23.402
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 22.925
SSH3 slingshot homolog 3 22.758
STIP1 stress-induced-phosphoprotein 1 22.594
SORBS2 sorbin and SH3 domain containing 2 22.572
EPN1 epsin 1 22.562
FGFR2 fibroblast growth factor receptor 2 22.551
RPS27A ribosomal protein S27a 22.494
MACF1 microtubule-actin crosslinking factor 1 22.458
The top ten genes up-regulated and down-regulated the most by the 50 mM
rosiglitazone treatment, with respect to DMSO-treated CaCo-2 cells.
doi:10.1371/journal.pone.0040149.t002
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Table 3. The top ten genes modulated by AS601245.
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 +5.329
AP3D1 adaptor-related protein complex 3, delta 1 subunit +3.634
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive +3.048
BMP2K bone morphogenetic protein 2 inducible kinase +2.889
DLST dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) +2.839
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) +2.830
MGA MAX gene associated +2.361
THRAP3 thyroid hormone receptor associated protein 3 +2.360
GANAB glucosidase, alpha; neutral AB +2.321
TWF1 twinfilin, actin-binding protein, homolog 1 +2.175
RPS27A ribosomal protein S27a 24.163
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 24.084
WDR33 WD repeat domain 33 23.869
EPN1 epsin 1 23.662
KLC2 kinesin light chain 2 23.657
STIP1 stress-induced-phosphoprotein 1 23.591
SEPT9 septin 9 23.409
TFDP1 transcription factor Dp-1 23.141
LAD1 ladinin 1 23.134
C16ORF58 chromosome 16 open reading frame 58 23.121
The top ten genes up-regulated and down-regulated the most by the 0.1 mM AS601245 treatment, with respect to DMSO-treated CaCo-2 cells.
doi:10.1371/journal.pone.0040149.t003
Table 4. The top ten genes modulated by the treatment with rosiglitazone + AS601245.
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 +11.092
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) +4.150
MT1X metallothionein 1X +4.047
AP3D1 adaptor-related protein complex 3, delta 1 subunit +3.945
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive +3.891
GANAB glucosidase, alpha; neutral AB +3.693
CPT1A carnitine palmitoyltransferase 1A +3.677
MT1G metallothionein 1G +3.651
MT1E metallothionein 1E +3.527
PLAUR plasminogen activator, urokinase receptor +3.412
FGA fibrinogen alpha chain 25.578
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 24.917
SI sucrase-isomaltase (alpha-glucosidase 23.944
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 23.848
FGG fibrinogen gamma chain 23.733
ANXA9 annexin A9 23.665
G0S2 G0/G1switch 2 23.506
FGB fibrinogen beta chain 23.174
DEFB1 defensin, beta 1 23.137
FGFR2 fibroblast growth factor receptor 2 23.183
The top ten genes up-regulated and down-regulated the most by combined treatment with 50 mM rosiglitazone and 0.1 mM AS601245, with respect to DMSO-treated
CaCo-2 cells.
doi:10.1371/journal.pone.0040149.t004
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RealTime RT-PCR
To confirm the Affymetrix results, we selected 5 genes that
had shown a .2-fold change in expression for further study by
real time PCR in a separate experiment. Two of these (GANAB
and MT2A) were found to be increased in Affymetrix analysis,
whereas the others two were found to be decreased (FGA and
FGFR2). Finally, one gene (ARHGEF7) was found to be highly
decreased in combined treatment, only. Moreover, we analysed
the expression of the three chains of fibrinogen in CaCo-2,
HT29 and SW480 cells. Cells were treated with 1% DMSO as
the vehicle or with 50 mM rosiglitazone, 0.1 mM AS601245, or
rosiglitazone plus AS601245 for 24 hours; total RNA from 3
biological replicates of each treatment was isolated using TRIzol
reagent (Invitrogen, Milano, Italy), then total RNA was
quantified with a NanoDrop (Thermo scientific) spectrophotom-
eter to measure RNA concentration and analyzed on an Agilent
2100 Bioanalyser to monitor RNA quality and integrity. Total
RNA was reverse transcribed into cDNA in a 20 ml reaction
using the TaqManH High Capacity cDNA Reverse Transcrip-
tion Kit provided by Applied Biosystems. 500 ng of total RNA
was used as the starting material from each sample. For each
RealTime PCR reaction, the reverse transcribed sample was
used as a template. To test assay linearity, a cDNA pool was
first serially diluted. Reactions were carried out in the presence
of the commercial TaqManH Gene Expression Assays and a 16
concentration of the TaqManH Universal PCR Master Mix
(Applied Biosystems). Target mRNA was quantified using an
ABI 7900 HT Fast RealTime PCR system (Applied Biosystems).
Primers were purchased from Applied Biosystems: GANAB
(glucosidase, alpha; neutral AB, Hs00929274_m1), MT2A
Table 5. Up-regulated genes containing PPRE sequences.
Rosiglitazone
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 9.691
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 3.707
DUSP6 dual specificity phosphatase 6 1.987
KLF4 Kruppel-like factor 4 1.92
HOXB8 homeobox B8 1.703
ADFP adipose differentiation-related protein 1.584
FABP1 fatty acid binding protein 1, liver 1.441
AS601245
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 5.329
Rosiglitazone + AS601245
Gene ID Gene name Fold-Change
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 11.092
PANK2 pantothenate kinase 2 2.966
DUSP6 dual specificity phosphatase 6 2.933
MARCKS myristoylated alanine-rich protein kinase C substrate 2.275
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 2.264
KLF4 Kruppel-like factor 4 2.201
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 2.114
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 2.082
ANKRD12 ankyrin repeat domain 12 1.975
SPEN spen homolog, transcriptional regulator 1.953
LMCD1 LIM and cysteine-rich domains 1 1.875
ADFP adipose differentiation-related protein 1.864
FOSL1 FOS-like antigen 1 1.844
FMNL2 formin-like 2 1.751
KLF5 Kruppel-like factor 5 1.526
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.521
LNPEP leucyl/cystinyl aminopeptidase 1.406
The genes harbouring PPRE sequences among the up-regulated genes by treatment with 50 mM rosiglitazone, 0.1 mM AS601245 and combined treatment versus
DMSO-treated CaCo-2 cells.
doi:10.1371/journal.pone.0040149.t005
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(metallothionein 2A, Hs02379661_g1), FGA (fibrinogen alpha
chain, Hs00241027_m1), FGB (fibrinogen beta chain
Hs00905942_m1) FGG (fibrinogen gamma chain
Hs00241037_m1) FGFR2 (fibroblast growth factor receptor 2,
Hs01552926_m1) and ARHGEF7 (Rho guanine nucleotide
exchange factor (GEF) 7, Hs00388776_m1). The TaqMan
probes were labelled with a 5’ reporter dye (FAM, 6-
carboxyfluorescein) and a 3’ quencher dye (TAMRA, 6-
carboxytetramethylrhodamine). RealTime PCR reactions were
carried out in triplicate in microamp optical 384-well plates in a
total volume of 10 ml/well. Data were analyzed by the ABI
Sequence Detection System (SDS) software using the relative
quantification. The fold changes are determined by the DDCt
method as described in Applied Biosystems User Bulletin No. 2.
Briefly, the level of each target mRNA was normalized to the
level of the 18S ribosomal RNA (housekeeping gene) in order to
obtain the DCt and then the DDCt was calculated against the
DMSO treatment.
b-PIX Transfection
The b-PIX plasmide was purchased by Qiagen (EIM0195303),
propagated in Escherichia coli Competent Cells (Promega)
following standard procedures and purified employing the Endo-
Free Plasmide Midi Kit (Qiagen). For transient transfection
experiments, CaCo-2, HT29 and SW-480 cells were grown in
six-wells plate at 80% confluence, 6 mg of purified plasmide
constructs were transfected using Lipofectamine 2000 reagent
(Invitrogen), according to the manufacturer’s instruction. b-PIX
expression was evaluated 24 hours after transfection, by western
blot. For negative control, pQE-TriSystem-6 Vector (Qiagen) was
used. At least three independent experiments for each condition
were performed.
Statistical Analysis
The 2-way ANOVA was performed in the proliferation,
adhesion, migration, fibrinogen release tests and densitometric
analysis of western blots.
Results
Rosiglitazone and AS601245 Affect Cell Proliferation
Preliminary experiments demonstrated that cell proliferation
was affected by rosiglitazone and by AS601245 until 96 hours, in a
concentration-dependent way in all three lines of colon cancer
cells tested (Fig. 1). However, the drug doses effective in inhibiting
cell proliferation by 50% (IC50) were rather high. In CaCo-2 cells,
IC50 was 150625 mM for rosiglitazone and 2.561 mM for
AS601245. The doses able to reduce cell proliferation by 20%
(IC20) were: 50 mM 612 for rosiglitazone and 0.1 mM 60.1 for
AS601245. IC50 and IC20 doses were very similar in all three cell
lines tested. The IC20 doses of rosiglitazone and AS601245,
defined in CaCo-2 cells, were then used for the microarray
experiments in this cell line.
Cell Adhesion and Migration After Rosiglitazone and
AS601245 Treatments
In the adhesion assay, performed after 24 hours from the start of
treatment, the addition of 50 mM rosiglitazone alone resulted in a
reduction of cell adhesion to HUVEC by about 55% in CaCo-2
cells and by 58% and 59% in HT29 and SW480 cells, respectively
(Fig. 2). The level of inhibition was gradually reduced by treating
the cells with lower doses of rosiglitazone. In a first set of
experiments, cell adhesion capacity was assayed in HCT116 cells,
also. In this cell line, cell adhesion was inhibited by 71% after
treatment with 50 mM rosiglitazone and by 59% after treatment
with 10 mM rosiglitazone (data not shown). The treatment with
50 mM AS60124 reduced the adhesion by about 55, 72 and 60%
in CaCo-2, HT29 and SW480 cells, respectively. The percentage
of inhibition was gradually reduced by treating the cells with lower
doses of AS601245 and the treatment with 0.1 mM AS601245 did
not significantly affect this parameter. To verify whether the
combined treatment of rosiglitazone and AS601245 could have an
additive effect in inhibiting cell adhesion, 0.1 mM AS601245 was
associated with increasing doses of rosiglitazone. In all three cell
lines the combination of 0.1 mM rosiglitazone with 0.1 mM
AS601245 showed an additive effect in reducing cell adhesion.
The combined treatment of 0.1 mM AS601245 with the higher
doses of rosiglitazone increased the effect of rosiglitazone alone
reaching the maximum level of inhibition. All three types of cells
showed a similar response to the treatments.
Migration was examined in CaCo-2, HT29, and SW480 cell
lines. The number of migrated cells/microscope field in untreated
control cells was 4568 for CaCo-2 cells, 5063 for HT29 cells and
4063 for SW480 cells. The value of migration of control cells
exposed to the vehicle (1% DMSO) was 4466 for CaCo-2 cells,
5168 for HT29 cells and 4065 for SW480 cells. Moreover, to
exclude that the results obtained in treated cells may depend on
cell proliferation, we analysed cell migration in untreated cells and
in cells treated for 24 hours with the highest concentrations of
rosiglitazone or AS601245 (50 mM) in presence of mitomycin C.
Results obtained demonstrated that the migration values were
similar in absence or in presence of mitomycin C (cells/
microscope field was 4568 for control CaCo-2 cells and 4466
for CaCo-2 control cells treated with mitomycin; 5063 for control
HT29 cells and 4965 for cells treated with mitomycin; 4063 for
control SW480 cells and 4268 for cells treated with mitomycin).
The percentages of inhibition in rosiglitazone treated cells were:
65% and 64% for CaCo-2 cells, 79% and 80% for HT29 cells and
60% and 63% for SW480, with and without mitomycin,
respectively; the percentages of inhibition of AS601245 treated
cells were: 55% and 50% for CaCo-2 cells, 80% and 75% for
HT29 cells and 92% and 87% for SW480 cells, with and without
mitomycin, respectively).
In Fig. 3 are reported the migration results obtained in cells
treated with rosiglitazone, AS601245 and both substances,
expressed as the percentage of inhibition with respect the
migration of cells exposed to the vehicle only (1% DMSO). The
migration was significantly inhibited by 10 and 50 mM rosiglita-
zone and AS601245 in all three cell lines. The treatments with
different combinations of concentrations under 50 mM of both
compounds produced an additive effect in inhibiting cell
migration. The combined treatment with concentrations of
50 mM rosiglitazone or AS601245 did not produce additive effects
(data not shown), probably because these concentrations, alone,
produced a percentage of inhibition close to the plateau.
Microarray Analysis of Gene Expression in CaCo-2 Cells
To analyze whether the cell responses to the treatments with
rosiglitazone, AS601245 or with both substances were a conse-
quence of a specific gene pathway modulation, we performed the
microarray analysis by using the Affimetryx GeneChip platform.
Since the inhibition of cell adhesion and migration by rosiglitazone
and AS601245 was very similar in all three cell lines of colon
cancer examined, we select CaCo-2 cell line to perform this
analysis, 24 hours after the treatments. The doses used in this study
were those able to induce an IC20 inhibition of CaCo-2 cell
proliferation (50 mM rosiglitazone and 0.1 mM AS601245).
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Figure 6. b-PIX protein expression.Western blot analysis of b-PIX expression in CaCo-2, HT29 and SW480 cells, treated for 24 hours with different
concentrations of rosiglitazone (1, 10, 50 mM), AS601245 (0.1, 1, 10) and combined treatment with 50 mM rosiglitazone and 0.1 mM AS601245. Equal
protein loading was confirmed by exposure of the membranes to the anti-b-actin antibody. Quantification of protein products (on the right) was
performed by densitometric scanning. Data are normalized using the b-actin signal and are indicated as means 6 SD from three independent
experiments. (A) Western blot analysis of CaCo-2 cells and relative densitometric values. (B) Western blot analysis of HT29 cells and relative
densitometric values. (C) Western blot analysis of SW480 cells and relative densitometric values. Variance analysis: * p,0.05, **p,0.01 vs control or
rosiglitazone treated cells.
doi:10.1371/journal.pone.0040149.g006
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The number of genes significantly modulated by rosiglitazone
and by AS601245 was very high. The complete list of the genes
modulated by rosiglitazone, AS601245 and by the combined
treatment is reported in the Supporting Information S1. The Venn
diagram (Fig. 4) shows that rosiglitazone modulated 1260 genes,
AS601245 modulated 3245 genes and, the combined treatments
modulated 1188 genes. Among the genes affected by rosiglitazone
alone or AS601245 alone, 1118 were common in both of the two
groups. The combined treatment affected 735 genes which were
present in both the rosiglitazone and AS601245 groups, and 173
genes which were not affected by either rosiglitazone or
AS601245, alone. Table 1 indicates the genes affected by
rosiglitazone, by AS601245, and by the combined treatment with
rosiglitazone and AS601245, arranged with respect to the relative
biological functions and listed on the basis of the p-value. The
genes mainly affected by both individual treatments belong to
cancer, genetic disorders, cell cycle, cell death and gastrointestinal
disease groups. The combined treatments affected mainly genes
belonging to cancer and cell death functions.
The top ten genes changed the most by the rosiglitazone
treatment, with respect to 1% DMSO treated cells, are reported in
Tab. 2. Rosiglitazone treatment mainly increased the CYP1A1
(9.6 fold change) gene expression which encodes a member of the
cytochrome P450 superfamily of enzymes and increased (from
6.06 to 2.79 fold changes) the expression of a group of genes
coding for metallothioneins (MT1X, MT1E, MT1G, MT1H,
MT2A, MT1M). Among genes down-regulated by rosiglitazone,
the first was the FGA gene (23.42 fold change). The other genes
which codify for the fibrinogen chains (FGB and FGG) were down
regulated by 22.29 and 22.02 fold, respectively. Other genes
down-regulated by rosiglitazone belonged mainly to two functional
groups: ‘‘cancer’’ (RPS27A, SORBS2, STIP1, FGA, FGFR2,
SSH3, EPN1) and cell death (SORBS2, STIP1, GAS2, EPN1).
Tab.3 illustrates the genes modulated by the treatments with
AS601245 with respect to 1% DMSO treated cells. In this case
also, the gene most up-regulated was CYP1A1 (5.329 fold change).
The other genes up-regulated belonged mainly to the ‘‘growth of
cells’’ function (BMO2K, DLST, IL6ST, MGA) and the
‘‘transcription’’ function (NFAT5 and THRAP3). The down-
regulated genes belonged mainly to the ‘‘cancer’’ biofunction
(RPS27A, HNRNPA1, STIP1 and TFDP1).
After combined treatment with rosiglitazone and AS601245
(Tab. 4) the major part of the top ten up-regulated genes were up-
regulated by treatments with the single substances, also. CYP1A1
was up-regulated by 11.09 fold. IL6ST was induced by AS601245
(2.8 fold change) and by the combined treatments (4.1 fold
change). Metallothionein genes were induced by the combined
treatment to a lesser extent than that determined by rosiglitazone
treatment. Conversely, the up-regulation of AP3D1 and NFAT5
after combined treatment was similar to that observed after
treatment with AS601245 alone. Among the down-regulated
genes, the three genes codifying the fibrinogen chains (a, b, c )
reached the top ten positions, while they were down-regulated to a
lesser extent by rosiglitazone alone. Moreover, ARHGEF7 (Rho
guanine nucleotide exchange factor)/bPIX gene was highly down-
regulated by the combined treatment.
Among the genes up regulated by the rosiglitazone treatment,
only a few have a PPRE putative sequence in the promoter,
indicating that the major part of rosiglitazone functions were
developed in a PPARc-independent way. Since the inhibition of
JNK could increase the affinity of activated PPARc for the PPRE
sequences, we investigated, among the genes activated by
rosiglitazone, by AS601245 and by the combined treatment, the
genes having PPRE sequences by using the genome-wide library of
high-confidence predicted PPAR target genes as published by
Lemay and collaborators [27] (Tab. 5). It is noteworthy that, after
combined treatments, the number of activated genes, containing
PPRE sequences, greatly increased (7 genes were up-regulated,
after treatment with rosiglitazone alone, and 17 genes were up-
regulated, after the combined treatment).
Table 6. Gene expression detected by affymetrix and quantitative Real-Time PCR.
Rosiglitazone AS601245 Rosiglitazone+AS601245
Gene Affymetrix qPCR (TaqMan) Affymetrix qPCR (TaqMan) Affymetrix qPCR (TaqMan)
GANAB 3.2 2.5 2.3 2.8 3.7 2.8
MT2A 4.4 5.1 unchanged 21.2 3.0 5.1
FGA 23.4 22.8 unchanged 22.0 25.6 24.7
FGFR2 22.6 22.2 22.1 21.7 23.2 23.5
ARHGEF7 21.4 22.1 21.7 21.8 24.9 24.2
Gene expression detected by affymetrix and quantitative real-time reverse transcription PCR in CaCo-2 cells treated with 50 mM rosiglitazone, 0.1 mM AS601245 and
combined treatment. Results are expressed as fold change versus DMSO-treated control cells.
doi:10.1371/journal.pone.0040149.t006
Table 7. Expression of fibrinogen chains detected by
quantitative Real Time PCR.
Cell line Gene Rosiglitazione AS601245
Rosiglitazone +
AS601245
CaCo-2 FGA 22,8 22,0 24.7
FGB 22.2 21.5 23.0
FGG 21.8 21.9 23.6
HT29 FGA 21.4 22.4 23.8
FGB 21.4 21.6 22.4
FGG 21.6 21.5 22.8
SW480 FGA n.d. n.d. n.d.
FGB 21.4 22.9 23.1
FGG 21.6 21.2 23.7
Expression of fibrinogen chains (FGA: fibrinogen chain a; FGB: fibrinogen chain
b; FGG: fibrinogen chain c) detected by quantitative real time reverse
transcription PCR, in cells treated with 50 mM rosiglitazone, 0.1 mM AS601245
and combined treatment. Results are expressed as fold change versus DMSO-
treated control cells. n.d.: not detectable.
doi:10.1371/journal.pone.0040149.t007
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Gene Expression Evaluation by RealTime PCR
To confirm results obtained by microarray analysis, RealTime
PCR of 5 selected genes (2 up-regulated and 3 down-regulated)
was performed. Results, reported in Tab. 6, indicated that the up
or down fold changes obtained by microarray analysis were similar
to those obtained in RealTime PCR. Some discrepancies were
found only for MT2A and FGA that did not change in AS601245
treated cells if evaluated in microarray analysis, whereas they were
decreased by 21.2 and 22 fold, respectively, if analysed in
RealTime PCR.
To assess whether the inhibition of the expression of the three
chains of fibrinogen, observed after rosiglitazone, AS601245 and
combined treatment with 50 mM rosiglitazone and 0.1 mM
AS601245, was a common response of the colon cancer cells,
we determined by RealTime PCR the expression of the three
chains of fibrinogen in CaCo-2, HT29 and SW480 cells. Results
obtained are reported in Tab 7 and demonstrated that the
inhibition of the expression of fibrinogen chains (except for SW480
cells, in which the a chain of fibrinogen is not detectable) was a
common response to the treatments of all three cell lines.
Fibrinogen Release
Since the expression of all three chains of fibrinogen are highly
down-regulated by combined treatment with rosiglitazone and
AS601245, the release of fibrinogen from CaCo-2 cells in the
culture medium was determined in control cells, in cells treated
with a single compound (50, 10 and 1 mM rosiglitazone or
0.1 mM AS601245) and in cells treated with both substances
(50 mM rosiglitazone plus 0.1 mM AS601245). Results, reported
in Fig. 5, indicate that rosiglitazone reduced in a dose-dependent
way the amount of fibrinogen released in the culture medium (a
47.2% reduction after treatment with 50 mM rosiglitazone and a
42% reduction after treatment with 10 mM rosiglitazone),
whereas 1 mM rosiglitazone or 0.1 mM AS601245 did not
significantly affect this parameter. Interestingly, the reduction of
fibrinogen release after combined treatment with 50 mM
rosiglitazone and 0.1 mM AS601245 was significantly higher (a
60% reduction) than that produced by the treatment with 50 mM
rosiglitazone, alone.
Evaluation of b-PIX Protein Expression in CaCo-2, HT29
and SW480 Colon Cancer Cells
Since the microarray analysis and real-time PCR indicated that
ARHGEF7/b-PIX gene was highly down-regulated after com-
bined treatment with rosiglitazone and AS601245, we analysed
the expression of b-PIX protein in CaCo-2 cells, and in the other
cell lines of colon cancer previously examined in this study: HT29
and SW480 cells. The b-PIX expression was analysed after
treatment with 1, 10 and 50 mM rosiglitazone, 0.1, 1 and 10 mM
AS601245, and after combined treatment with 50 mM rosiglita-
zone and 0.1 mM AS601245. Results indicated that both
rosiglitazone and AS601245 decreased in a dose-dependent way
the b-PIX expression, starting from 10 mM rosiglitazone and
1 mM AS601245 in CaCo-2 cells, while in the other two lines the
Figure 7. Migration of b-PIX transfected colon cancer cells. A. Western blot expression of CaCo-2, HT29 and SW480 cells of control and
transfected with the empty plasmide and with the plasmide carrying b-PIX gene. B. Inhibition of tumour cell invasion by a Boyden chamber assay in
cells tranfected with b-PIX carrying plasmide. Control cells and transfected cells were plated onto the apical side of Matrigel-coated filters in serum-
free medium supplemented with drugs at different concentrations (10, 50 mM rosiglitazone; 0.1, 1, 10, 50 mM AS601245) and with the association of
different drug concentrations for 24 hours. Chemoattractant utilized was 20% FCS supplemented medium, placed in the basolateral chamber. The
cells migrated to the bottom of the filters were stained using crystalviolet and counted (5 fields of each triplicate filters) using an inverted
microscope. Control migration was 4568, 5168 and 3364 cells/microscope field for CaCo-2, HT29, SW480 cells, respectively, and 4965, 5066 and
3066 cells/microscope field for CaCo-2, HT29 and SW480 cells, respectively, after transfection with b-PIX carrying plasmide and empty plasmide. Data
are expressed as mean 6 SEM (n= 5) of the percentage of inhibition versus the control migration.
doi:10.1371/journal.pone.0040149.g007
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dose-dependence was not so evident (Fig. 6). Combined treatment
was more effective in decreasing the b-PIX expression than the
treatments with the highest dose of rosiglitazone in HT29 and
SW480 cells, whereas in CaCo-2 cells the effect of combined
treatment was not so evident.
Evaluation of Cell Migration in b-PIX Transfected Cells
To asses the role of b-PIX protein as a target for the
rosiglitazone and AS601245 inhibitory effect on cell invasiveness,
we performed transient transfection of CaCo-2, HT20 and SW480
cells with plasmide constructs containing the b-PIX gene, as
described under ‘‘Materials and Methods. Fig. 7 (panel A) shows
b-PIX expression in CaCo-2, HT29 and SW480 cells and in cells
transfected with the plasmide empty or containing b-PIX gene.
The transfection with b-PIX gene resulted in a 6 fold increase of b-
PIX protein with respect to the CaCo-2 control cells and about a 4
fold increase of b-PIX protein with respect to the HT29 an SW480
control cells.
To verify whether the endogenous increase of b-PIX protein
could affect the response to the rosiglitazone and AS60124
treatment, we analysed the migration capacity after drug
treatment in control and transfected cells. Fig. 7 (panel B) reports
the percentage of migration inhibition, with respect to the
untreated cells, 24 hours after treatment with different concentra-
tions of rosiglitazone and AS601245 and the combinations of two
drugs. The b-PIX transfection abrogated the inhibition of cell
migration determined by rosiglitazone, AS601245 and combined
treatment in all three cell lines, thus indicating that b-PIX protein
was an important target for rosiglitazone and AS601245 inhibitory
action.
Discussion
Results obtained demonstrated that the combined treatment
with rosiglitazone and AS601245 increases the anticancer effects
of the two substances in colon cancer cells. In particular cell
adhesion and migration were reduced by the rosiglitazone alone
and they were further reduced by the combined treatment of
rosiglitazone and AS601245.
In this paper we demonstrated that rosiglitazone strongly
inhibited cell adhesion at doses (1 mM) ineffective in modulating
other parameters. This important datum may be related to the
inhibition of expression of all fibrinogen chains (FGA, FGB and
FGG) caused by rosiglitazone alone (FGA was inhibited by
23.426 fold, FGB by 22.09 fold and FGG by 22.02 fold).
Interestingly, both inhibition of cell adhesion and the inhibition of
fibrinogen chain expressions were enhanced by the combined
treatment with the JNK inhibitor and rosiglitazone. Although little
literature data is available about the effect of PPAR ligands in cell
adhesion, Reddy and collaborators [28] reported that PPARc
ligands inhibited chemotaxis of PMN suggesting that PPAR
ligands influence cell adhesion and migration. Moreover, we
demonstrated that rosiglitazone not only inhibited fibrinogen
chain expressions, but also reduced the amount of fibrinogen
released by the cells. It is well known that the increase of
fibrin(ogen) is correlated with an increase of risk of metastasis [29].
These results may suggest that PPARc ligands could effectively
inhibit the first steps of the metastatic process.
The results obtained about the inhibition of migration by
rosiglitazone and AS601245 also support the hypothesis that
PPARc ligands and anti-inflammatory drugs can reduce cancer
cell invasiveness. Recently it has been demonstrated that PPAR c
agonists 15d-PGJ(2) and rosiglitazone significantly reduced eosin-
ophil migration into the peritoneal cavity [30] and that ciglitazone
reduced both wound-induced migration and chemotaxis of breast
cancer cells [31] in a PPARc-dependent and PPARc-independent
manner. As far as it regards JNK inhibitors in the control of cell
migration and invasion, it has been reported that JNK2-selective
peptide inhibitors inhibited breast cancer cell migration [32] and
that JNK suppression inhibited cell migration in human LoVo
colon cancer cells [33].
The results obtained in the microarray experiments suggested
that the ARHGEF7/b-PIX gene could be an important target for
rosiglitazone and AS601245 action. The inhibition of b-PIX
expression was confirmed by the RealTime PCR and western blot
analysis. Interestingly, b-PIX protein content was decreased, by
rosiglitazone and AS601245, in all three lines of colon cancer,
suggesting that this effect could be a common feature of
rosiglitazone and AS601245 action.
b-PIX protein belongs to a family of cytoplasmic proteins that
activate the Ras-like family of Rho proteins by exchanging bound
GDP for GTP. It forms a complex with the small GTP binding
protein Rac1 and recruits Rac1 to membrane ruffles and to focal
adhesions [34]. The small GTPase Rac1 is a well-characterized
modulator of cell migration [34]. In addition, the role of b-PIX in
cell migration has recently been stressed by the results demon-
strating that the restoration of b-PIX expression by genetic
manipulation, restored the migratory ability of mesenchymal
stromal cells (MDCs) from patients of amyotrophic lateral
sclerosis, and the inhibition of b-PIX expression with shRNA,
reduced the migration of healthy MSCs [35]. On the basis of these
results, we postulated that b-PIX protein could be involved in the
rosiglitazone and AS601245 inhibition of cell migration. Indeed,
the results obtained by the transfection experiments confirmed the
role played by b-PIX protein in this contest, since our data
demonstrated, for the first time, that b-PIX transfection
completely abrogates the inhibition of colon cancer cell migration
caused by rosiglitazone, AS601245 or by combined treatment with
both compounds.
Although the treatment with 0.1 mM AS601245 increased the
number of PPRE containing genes activated by 50 mM rosiglita-
zone, the most quantitatively important genes up-modulated by
rosiglitazone are the metallothionein genes (MT1X, MT1E,
MT1G, MT1H, MT2A) which do not contain PPRE sequences.
Metallothionein genes can be induced by anti-inflammatory
agents such as dexamethasone [36] and nonsteroidal anti-
inflammatory drugs, such as chloroquina, diclofenac and indome-
tacin [37]. Metallothioneins provide protection against metal
toxicity [38] and oxidative stress [39]. In cancer cells, metallo-
thionein expressions are increased, decreased or not changed in
relation to the cancer types [40]. In particular, a significant
decrease in the amount of metallothionein proteins in colorectal
adenoma and carcinoma, as compared with normal colorectal
mucosa, has been reported [41]. Thus, the increase of metallo-
thionein expression by rosiglitazone may be ascribed to both the
anti-neoplastic and anti-inflammatory effects exerted by rosiglita-
zone in colon cancer cells [42].
Taken together, our data demonstrated, in colon cancer cells,
the effectiveness of combined treatments with PPARc agonists
and a JNK inhibitor in reducing cell adhesion and migration,
and are in agreement to the data indicating a positive interaction
between PPARc ligands and anti-inflammatory agents in humans
[43].
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